4D Molecular Therapeutics, Inc.
FDMT
$11.22
$0.524.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -56.88M | -54.66M | -47.97M | -49.67M | -43.84M |
| Total Depreciation and Amortization | 2.00M | 1.89M | 1.75M | 1.78M | 1.70M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.38M | 3.80M | 5.63M | 5.74M | 4.29M |
| Change in Net Operating Assets | 5.00M | 5.59M | -7.17M | -3.72M | 8.46M |
| Cash from Operations | -46.50M | -43.38M | -47.76M | -45.86M | -29.39M |
| Capital Expenditure | 91.00K | -66.00K | -631.00K | -949.00K | -1.78M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 17.69M | -13.79M | 32.58M | 8.01M | 29.08M |
| Cash from Investing | 17.78M | -13.85M | 31.95M | 7.06M | 27.30M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 116.00K | 862.00K | -- | 601.00K | 568.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 116.00K | 862.00K | -- | 601.00K | 568.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -28.60M | -56.37M | -15.81M | -38.20M | -1.52M |